Delivers like nothing else.
Ranger DCB is built on the physician preferred Sterling™ 0.014”/0.018” balloon platform1 with a low entry profile.
BOLD CLINICAL TRIALS
Two randomised control trials.1,2
Bold is being the first company to voluntarily evaluate our Drug-Coated Balloon against another DCB in a Level-1 Randomised Controlled Trial for comparative effectiveness. Ranger™ DCB demonstrated similar primary patency as IN.PACT with half the total drug dose5 at 2-Years. And consistently demonstrated high primary patency, near 90%, at 1-Year in the RANGER II SFA & COMPARE Trials6.
Exceptional outcomes at 2-Years7. No matter the lesion complexity. No matter the patient.
In the RANGER II SFA RCT, Ranger demonstrated 84% K-M primary patency at 2-Years.7
Explore DE Resources
Get physician perspectives, clinical data sheets and other resources about drug-eluting innovations.
Stay Up to Date
Receive emails about the latest drug-eluting technology news, innovations and events in your area.